Prostate Cancer Risk Potentially Decreased by Following the Mediterranean Diet
Fish oil capsules, cod liver, and salmon fillet on wooden surface
January 11, 2021
Share
It is important for cancer patients to eat right and get adequate nutrition. The two diets known to be associated with longevity and reduced risks for prostate cancer are the traditional Japanese diet and a Southern Mediterranean diet (MD). Now researchers from the University of Texas MD Anderson Cancer Center found that men with localized prostate cancer (PCa) who reported a baseline dietary pattern that more closely follows the key principles of a Mediterranean-style diet fared better over the course of their disease.
Dive Brief:
Dana-Farber Cancer Institute is diving deeper into biotech financing, announcing Thursday the launch of Binney Street Capital, its first-ever venture fund.
Binney will support new research and technologies as part of the institute s larger mission to help treat incurable cancers. The fund plans to invest in eight to 10 companies over the next three years, providing between $250,000 and $2 million per investment, according to Luba Greenwood, a veteran life sciences investor who will serve as Binney s managing partner.
Specifically, the money will go to startups that were either created using Dana-Farber s intellectual property, or co-founded by one of its investigators. The institute says Binney will primarily focus on companies developing new drugs, but could also invest in those working on health services, digital health and novel diagnostics.
Renowned experts challenge conventional wisdom across the imaging community
A special issue of the
Journal of the American College of Radiology (JACR), published by Elsevier, challenges conventional wisdom across the imaging community.
This collection of articles, the Provocative Issue, presents extreme opinions on pressing issues confronting radiologists with the deliberate aim of sparking positive dialog and debate that will lead to innovative solutions to improve patient care and imaging-related outcomes.
The issue is guest-edited by:
Caroline Chung, MD, MSc, Director of Advanced Imaging - Strategic Initiative and Director of Imaging Technology and Innovation, Department of Radiation Oncology and Diagnostic Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX, USA;
MD Anderson and UroGen today announced a strategic three-year collaboration agreement to advance combination immunotherapy, delivered directly into the bladder, for the treatment of high-grade non-muscle invasive bladder cancer. The collaboration will work through MD Anderson s immunotherapy platform to design pre-clinical and clinical studies.